Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1643 1646
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17854649 | METHODS OF INDUCING NEOEPITOPE-SPECIFIC T CELLS WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE | Non-Final OA | Hoffmann-La Roche Inc. |
| 17596118 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH COLLAGEN BINDING DRUG CARRIERS | Final Rejection | The University of Chicago |
| 16755065 | TRANSGENIC SELECTION METHODS AND COMPOSITIONS | Final Rejection | The Jackson Laboratory |
| 17928778 | COMPOSITION COMPRISING HIF-1 ALPHA ANTIBODY FOR TREATING CANCER | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
| 17763251 | USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18330141 | COMBINATION THERAPY OF ANTI-PD-1 ACTIVE AGENT, ANTI-TIM-3 ACTIVE AGENT, AND ANTI-LAG-3 ACTIVE AGENT FOR TREATING CANCER | Non-Final OA | Incyte Corporation |
| 17782338 | A T cell-based immunotherapy for central nervous system viral infections and tumors | Final Rejection | YALE UNIVERSITY |
| 16978354 | ANTI-PD-1 ANTIBODY COMPOSITIONS | Final Rejection | PFIZER INC. |
| 17691050 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | Final Rejection | Janssen Biotech, Inc. |
| 18279380 | METHODS OF ENHANCING ANTIBODY THERAPIES | Non-Final OA | UNIVERSITY OF IOWA RESEARCH FOUNDATION |
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | Final Rejection | Merus N.V. |
| 18264819 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | Non-Final OA | JIANGXI JEMINCARE GROUP CO., LTD. |
| 18260364 | ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF | Non-Final OA | Palleon Pharmaceuticals Inc. |
| 18269615 | HER2 SINGLE DOMAIN ANTIBODIES VARIANTS AND CARS THEREOF | Non-Final OA | HONING BIOSCIENCES |
| 18030886 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION THERAPY | Final Rejection | Bio-Thera Solutions, Ltd. |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | Final Rejection | Seagen Inc. |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | Non-Final OA | SEAGEN INC. |
| 17604728 | ANTI-TRKA ANTIBODIES AND USES THEREOF | Non-Final OA | SUNSHINE LAKE PHARMA CO., LTD. |
| 17919923 | TREATMENT OF DISEASES WITH CLEVER-1 INHIBITION IN COMBINATION WITH AN INTERLEUKIN INHIBITOR | Non-Final OA | FARON PHARMACEUTICALS OY |
| 17955743 | Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis | Non-Final OA | Wuhan Ktai Biotechnology Company Limited |
| 17508973 | Treatment of brain ischemia-reperfusion injury | Final Rejection | XBiotech USA, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy